The KiSSim approach performs slightly worse compared to the KLIFS pocket sequence comparison in case of ligands like Imatinib, whose reported on-targets all belong to the TK group, but shows better performance for Erlotinib, Bosutinib, and Doramapimod, which have known kinase targets belonging to different kinase groups. Hence, while the sequencebased approach picks up kinase group assignments as to be expected, KiSSim picks up more distant and less obvious off-targets.